KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer

2010 ◽  
Vol 38 (12) ◽  
pp. 869-873 ◽  
Author(s):  
Giancarlo Troncone ◽  
Umberto Malapelle ◽  
Immacolata Cozzolino ◽  
Lucio Palombini
Keyword(s):  
Rectal Cancer ◽  
Mutation Analysis ◽  
Kras Mutation

scholarly journals KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

2011 ◽  
Vol 104 (6) ◽  
pp. 1020-1026 ◽  
Author(s):  
N Knijn ◽  
L J M Mekenkamp ◽  
M Klomp ◽  
M E Vink-Börger ◽  
J Tol ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Colorectal Cancer Patients

scholarly journals KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Yuurin Kondo ◽  
Kazuhiko Hayashi ◽  
Kazuyuki Kawakami ◽  
Yukari Miwa ◽  
Hiroshi Hayashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Mutation Analysis ◽  
Kras Mutation

scholarly journals Association between Texture Analysis Parameters and Molecular Biologic KRAS Mutation in Non-Mucinous Rectal Cancer

2020 ◽  
Vol 81 ◽  
Author(s):  
Sung Jae Jo ◽  
Seung Ho Kim ◽  
Sang Joon Park ◽  
Yedaun Lee ◽  
Jung Hee Son
Keyword(s):  
Rectal Cancer ◽  
Texture Analysis ◽  
Kras Mutation

Multi-branch cross attention model for prediction of KRAS mutation in rectal cancer with t2-weighted MRI

2020 ◽  
Vol 50 (8) ◽  
pp. 2352-2369
Author(s):  
JiaWen Wang ◽  
YanFen Cui ◽  
GuoHua Shi ◽  
JuanJuan Zhao ◽  
XiaoTang Yang ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Kras Mutation ◽  
Attention Model

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance

2012 ◽  
Vol 462 (1) ◽  
pp. 39-46 ◽  
Author(s):  
J. R. Dijkstra ◽  
D. A. M. Heideman ◽  
G. A. Meijer ◽  
J. E. Boers ◽  
N. A. ‘t Hart ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Quality Assurance ◽  
Cancer Cells ◽  
Mutation Analysis ◽  
Kras Mutation ◽  
Colon Cancer Cells

Preoperative chemoradiation with nimotuzumab and capecitabine in patients with locally advanced rectal cancer: A phase II study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14049-e14049
Author(s):  
Yuan Zhu ◽  
Luying Liu ◽  
Jialing Luo ◽  
Dechuan Li ◽  
Yuping Zhu
Keyword(s):  
Rectal Cancer ◽  
Kras Mutation ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Preoperative Chemoradiation ◽  
Pathologic Response ◽  
Study Endpoint ◽  
Mutation Status ◽  
Kras Mutation Status

e14049 Background: To evaluate the efficacy and safety of preoperative chemoradiation with Nimotuzumab(a humanized monoclonal antibody that targets and binds to the epidermal growth factor receptor)and capecitabine in the patients with locally advanced rectal cancer. Methods: Twelve patients with locally advanced, nonmetastatic, and mid- to lower rectal cancer were enrolled. Radiotherapy was delivered at a dose of 50 Gy/25 fractions. Concurrent therapy consisted of Nimotuzumab 400 mg/m2,1 week before radiotherapy, and then Nimotuzumab 400 mg/m2/week for 5 weeks, and capecitabine 1,650 mg/m2/day for 5 days a week (weekdays only) from the first day during radiotherapy. Three weeks after the end of chemoradiation, 1 cycle chemotherapy with oxaliplatin and capecitabine(XELOX) was performed. Oxaliplatin 130mg/m2, Day1 and capecitabine 1000 mg/m2, bid, from Day 1 to Day 14. Postoperative chemotherapy after surgery followed by preoperative CRT was in all patients, The same dosage of XELOX was started within 3 to 4 weeks after surgery, repeated every 3 weeks for 6 cycles. Total mesorectal excision was performed within 6 ~ 8 weeks. The pathologic response was evaluated as study endpoint, and an additional KRAS mutation analysis was performed. Results: In total, 9 patients completed their planned preoperative chemoradiation and underwent R0 resection. The pathologic complete response rate was 33.3% (3/9), and 3 patients (33.3%) showed near total regression of tumor. Grade 3 toxicities was diarrhea (2/12, 16.7 %), No grade 4 toxicity was observed. KRAS mutations were found in 2 of 12 patients (16.7%) who had available tissue for testing. Clinical outcomes were not significantly correlated with KRAS mutation status. Conclusions: Preoperative chemoradiation with Nimotuzumab and capecitabine was active and well tolerated. KRAS mutation status was not a predictive factor for pathologic response in this study.

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer

2012 ◽  
Vol 66 (8) ◽  
pp. 748-752 ◽  
Author(s):  
A. Pennycuick ◽  
T. Simpson ◽  
D. Crawley ◽  
R. Lal ◽  
G. Santis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mutation Analysis ◽  
Cell Lung Cancer ◽  
Kras Mutation ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Veronika Auner ◽  
Gernot Kriegshäuser ◽  
Dan Tong ◽  
Reinhard Horvat ◽  
Alexander Reinthaller ◽  
...  
Keyword(s):  
Mutation Analysis ◽  
Kras Mutation ◽  
High Sensitivity
Sign in / Sign up

Export Citation Format

Share Document